Regular intake of a usual serving size of flavanol-rich cocoa powder does not affect cardiometabolic parameters in stably treated patients with type 2 diabetes and hypertension—A double-blinded, randomized, placebo-controlled trial

Nutrients

Volumn 10, Issue 10, 2018, Pages

  Dicks, Lisa ^a,b   Kirch, Natalie ^a   Gronwald, Dorothea ^b   Wernken, Kerstin ^b   Zimmermann, Benno F ^c   Helfrich, Hans Peter ^c   Ellinger, Sabine ^a  

^a UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b diabetesPRAXIS Rathausallee   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Blood pressure; Flavanol rich cocoa; Glucose metabolism; Lipid status; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; FLAVONOL DERIVATIVE; LIPID; PLANT EXTRACT;

ADIPOSE TISSUE; AGED; BEVERAGE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CACAO; CARDIOVASCULAR DISEASE; CHOCOLATE; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PORTION SIZE; RANDOMIZED CONTROLLED TRIAL;

ADIPOSE TISSUE; AGED; BEVERAGES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CACAO; CARDIOVASCULAR DISEASES; CHOCOLATE; DIABETES MELLITUS, TYPE 2; DIET; DOUBLE-BLIND METHOD; FEMALE; FLAVONOLS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PLANT EXTRACTS; SERVING SIZE;

EID: 85054776985     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10101435     Document Type: Article

References (35)

1. American Diabetes Association (ADA). Standards of medical care in diabetes-2017. Diabetes Care 2017, 40, 1–135.
2. Turner, R.C.; Millns, H.; Neil, H.A.W.; Stratton, I.M.; Manley, S.E.; Matthews, D.R.; Holman, R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998, 316, 823–828. [CrossRef] [PubMed]
3. Alkhatib, A.; Tsang, C.; Tiss, A.; Bahorun, T.; Arefanian, H.; Barake, R.; Khadir, A.; Tuomilehto, J. Functional foods and lifestyle approaches for diabetes prevention and management. Nutrients 2017, 9, 1310. [CrossRef] [PubMed]
4. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.; Gross, H.B.; Keen, C.L.; Schroeter, H.; et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J. Am. Coll. Cardiol. 2008, 51, 2141–2149. [CrossRef] [PubMed]
5. Grassi, D.; Desideri, G.; Necozione, S.; Lippi, C.; Casale, R.; Properzi, G.; Blumberg, J.B.; Ferri, C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J. Nutr. 2008, 138, 1671–1676. [CrossRef] [PubMed]
6. Mellor, D.D.; Sathyapalan, T.; Kilpatrick, E.S.; Beckett, S.; Atkin, S.L. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in type 2 diabetes patients. Diabet. Med. 2010, 27, 1318–1321. [CrossRef] [PubMed]
7. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Casas, R.; Urpí-Sardà, M.; Llorach, R.; Lamuela-Raventós, R.M.; Estruch, R. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am. J. Clin. Nutr. 2009, 90, 1144–1150. [CrossRef] [PubMed]
8. Parsaeyan, N.; Mozaffari-Khosravi, H.; Absalan, A.; Mozayan, M.R. Beneficial effects of cocoa on lipid peroxidation and inflammatory markers in type 2 diabetic patients and investigation of probable interactions of cocoa active ingredients with prostaglandin synthase-2 (PTGS-2/COX-2) using virtual analysis. J. Diabetes Metab. Disord. 2014, 13, 1–9. [CrossRef] [PubMed]
9. Rostami, A.; Khalili, M.; Haghighat, N.; Eghtesadi, S.; Shidfar, F.; Heidari, I.; Ebrahimpour-Koujan, S.; Eghtesadi, M. High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. ARYA Atheroscler. 2015, 11, 21–29. [PubMed]
10. Ramos, S.; Martín, M.A.; Goya, L. Effects of cocoa antioxidants in type 2 diabetes mellitus. Antioxidants 2017, 6, 1–16. [CrossRef] [PubMed]
11. European Food Safety Authority (EFSA). Scientific opinion on the modification of the authorisation of a health claim related to cocoa flavanols and maintenance of normal endotheliumdependent vasodilation pursu-ant to Article 13(5) of Regulation (EC) No 1924/2006 following request in accordance with Article 19 of Regulation (EC) No 1924/2006. EFSA J. 2014, 12, 1–13.
12. Sena, C.M.; Pereira, A.M.; Seiça, R. Endothelial dysfunction-a major mediator of diabetic vascular disease. Biochim. Biophys. Acta. 2013, 1832, 2216–2231. [CrossRef] [PubMed]
13. Al-Tabakha, M.M. HPMC capsules: Current status and future prospects. J. Pharm. Pharm. Sci. 2010, 13, 428–442. [CrossRef] [PubMed]
14. World Health Organization (WHO); International Diabetes Federation (IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation. In Proceedings of the WHO Document Production Services, Geneva, Switzerland, 2006.
15. European Society of Hypertension (ESH); European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013, 34, 2159–2219. [CrossRef] [PubMed]
16. Damm, I.; Enger, E.; Chrubasik-Hausmann, S.; Schieber, A.; Zimmermann, B.F. Fast and comprehensive analysis of secondary metabolites in cocoa products using ultra high-performance liquid chromatography directly after pressurized liquid extraction. J. Sep. Sci. 2016, 39, 3113–3122. [CrossRef] [PubMed]
17. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [CrossRef] [PubMed]
18. World Health Organization (WHO). Waist Ccrcumference and waist-hip ratio: Report of a WHO expert consultation. 2011. Available online: http://apps.who.int/iris/bitstream/10665/44583/1/9789241501491_ eng.pdf (accessed on 7 May 2017).
19. Kyle, U.G.; Bosaeus, I.; de Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Manuel Gomez, J.; Lilienthal Heitmann, B.; Kent-Smith, L.; Melchior, J.-C.; Pirlich, M.; et al. Bioelectrical impedance analysis-part II: Utilization in clinical practice. Clin. Nutr. 2004, 23, 1430–1453. [CrossRef] [PubMed]
20. Kirch, N.; Berk, L.; Liegl, Y.; Adelsbach, M.; Zimmermann, B.F.; Stehle, P.; Stoffel-Wagner, B.; Ludwig, N.; Schieber, A.; Helfrich, H.-P.; et al. A nutritive dose of pure (-)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults-a randomized, placebo-controlled, double-blind crossover study. Am. J. Clin. Nutr. 2018, 107, 948–956. [CrossRef] [PubMed]
21. Kyle, U.G.; Genton, L.; Karsegard, L.; Slosman, D.O.; Pichard, C. Single prediction equation for bioelectrical impedance analysis in adults aged 20–94 years. Nutrition 2001, 17, 248–253. [CrossRef]
22. U.S. Department of Agriculture (USDA). Database for the Flavonoid Content of Selected Foods, Release 3.1 (December 2013). 2014. Available online: https://www.ars.usda.gov/northeast-area/beltsville-md/belt-ville-human-nutrition-research-center/nutrient-data-laboratory/docs/usda-database-for-the-flavonoid-content-of-selected-foods-release-31-december-2013/(accessed on 5 September 2016).
23. Ott, L. An Introduction to Statistical Methods and Data Analysis; Duxbury Press: North Scituate, MA, USA, 1977.
24. Ellinger, S.; Reusch, A.; Stehle, P.; Helfrich, H.-P. Epicatechin ingested via cocoa products reduces blood pressure in humans: A nonlinear regression model with a Bayesian approach. Am. J. Clin. Nutr. 2012, 95, 1365–1377. [CrossRef] [PubMed]
25. Turnbull, F.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003, 362, 1527–1535. [PubMed]
26. Lohman, T.G.; Roche, A.F.; Martorell, R. Anthropometric Standardization Reference Manual; Human Kinetics Books: Champaign, IL, USA, 1988.
27. Cooper, K.A.; Campos-Gimenez, E.; Jimenez Alvarez, D.; Nagy, K.; Donovan, J.L.; Williamson, G. Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. J. Agric. Food Chem. 2007, 55, 2841–2847. [CrossRef] [PubMed]
28. Grassi, D.; Desideri, G.; Necozione, S.; Di Giosia, P.; Barnabei, R.; Allegaert, L.; Bernaert, H.; Ferri, C. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. J. Hypertens. 2015, 33, 294–303. [CrossRef] [PubMed]
29. Meissner, K. Placebo responses on cardiovascular, gastrointestinal, and respiratory organ functions. Handb. Exp. Pharmacol. 2014, 225, 183–203. [PubMed]
30. Escolà-Gil, J.C.; Julve, J.; Griffin, B.A.; Freeman, D.; Blanco-Vaca, F. HDL and lifestyle interventions. Handb. Exp. Pharmacol. 2015, 224, 569–592. [PubMed]
31. Martin, M.Á.; Goya, L.; Ramos, S. Antidiabetic actions of cocoa flavanols. Mol. Nutr. Food Res. 2016, 60, 1727–1896. [CrossRef] [PubMed]
32. Strat, K.M.; Rowley, T.J.; Smithson, A.T.; Tessem, J.S.; Hulver, M.W.; Liu, D.; Davy, B.M.; Davy, K.P.; Neilson, A.P. Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders. J. Nutr. Biochem. 2016, 35, 1–21. [CrossRef] [PubMed]
33. Aprotosoaie, A.C.; Miron, A.; Trifan, A.; Luca, V.S.; Costache, I.-I. The cardiovascular effects of cocoa polyphenols-an overview. Diseases 2016, 4, 1–25. [CrossRef] [PubMed]
34. Ottaviani, J.I.; Kwik-Uribe, C.; Keen, C.L.; Schroeter, H. Intake of dietary procyanidins does not contribute to the pool of circulating flavanols in humans. Am. J. Clin. Nutr. 2012, 95, 851–858. [CrossRef] [PubMed]
35. 14C) (-)-epicatechin in humans: Implications for the assessment of efficacy, safety, and mechanisms of action of polyphenolic bioactives. Sci. Rep. 2016, 6, 29034. [CrossRef] [PubMed]